GNH USA

Europe — EMA

Nagilma (Metformin Hydrochloride, Linagliptin)

GNH USA supplies Nagilma (Metformin Hydrochloride and Linagliptin), a Biguanide/DPP‑4 inhibitor for type 2 diabetes mellitus. Request a quote for supply.

Metformin Hydrochloride, Linagliptin

Request sourcing

1
Pack/s

What is Metformin Hydrochloride, Linagliptin?

Metformin Hydrochloride and Linagliptin, the active ingredient in Nagilma, is a Biguanide/DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of type 2 diabetes mellitus in adult patients, helping to control blood glucose levels when diet and exercise are insufficient.

GNH USA supplies Nagilma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable and timely logistics through global distribution networks.

What is Metformin Hydrochloride, Linagliptin used for?

Nagilma, a combination of metformin and linagliptin, is used in the management of type 2 diabetes mellitus.

Type 2 diabetes mellitus (monotherapy): lowers fasting plasma glucose and HbA1c when diet and exercise are insufficient. Type 2 diabetes mellitus (add‑on to metformin): enhances post‑prandial glucose control in patients already on metformin. Type 2 diabetes mellitus (combined therapy): provides synergistic glucose reduction, improving overall glycemic control.

What are the side effects of Metformin Hydrochloride, Linagliptin?

Nagilma may cause adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Dizziness: transient episodes. - Metallic taste: occasional sensation.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic complication, especially in patients with renal impairment. - Severe hypoglycemia: may occur when combined with insulin or sulfonylureas. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain.

What precautions apply to Metformin Hydrochloride, Linagliptin?

When prescribing Nagilma, clinicians should consider several safety aspects.

Renal function: assess baseline creatinine clearance and monitor regularly. Hepatic function: use with caution in patients with liver disease. Lactic acidosis risk: avoid in severe renal impairment or conditions predisposing to hypoxia. Pregnancy and lactation: prescribe only if potential benefit justifies risk to fetus or infant. Drug interactions: review concomitant medications for agents affecting metformin or DPP‑4 inhibitor metabolism. Store at ambient temperature: keep in original container, protect from moisture and heat.

What does Metformin Hydrochloride, Linagliptin interact with?

Nagilma can interact with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Renal contrast agents: may precipitate metformin accumulation and lactic acidosis. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase linagliptin plasma levels. - Insulin or sulfonylureas: heightened risk of hypoglycemia. - Diuretics (e.g., furosemide): can reduce renal clearance of metformin. - Alcohol excess: potentiates risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of hypoglycemia. - ACE inhibitors or ARBs: monitor renal function when combined with metformin.

Frequently asked questions

What is Nagilma used for?+
Nagilma is indicated for the treatment of type 2 diabetes mellitus in adult patients. It combines metformin, which improves insulin sensitivity, with linagliptin, a DPP‑4 inhibitor that enhances insulin secretion, to provide better overall glycemic control when diet and exercise alone are insufficient.
How does Metformin Hydrochloride work?+
Metformin Hydrochloride lowers blood glucose primarily by reducing hepatic glucose production (gluconeogenesis) and by increasing peripheral tissue sensitivity to insulin. These actions help decrease fasting plasma glucose and improve overall glycemic balance without directly stimulating insulin release.
What is the usual dose of Nagilma?+
The specific dose of Nagilma is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy. Dosage adjustments are made according to standard medical guidelines and patient monitoring.
Is Nagilma safe during pregnancy or breastfeeding?+
Safety data for Nagilma in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.
How do I order Nagilma from GNH USA?+
To order Nagilma, submit an enquiry on the product page at gnh-usa.com specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.
How does Nagilma compare with other antidiabetic options?+
Nagilma combines two established mechanisms—metformin’s insulin‑sensitising effect and linagliptin’s DPP‑4 inhibition—offering a synergistic approach. Compared with metformin alone, it provides greater post‑prandial glucose control, and unlike sulfonylureas, it carries a lower intrinsic risk of hypoglycemia when used without other insulin‑secretagogues.
What are the storage requirements for Nagilma?+
Nagilma should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, direct sunlight, and excessive heat to maintain product stability throughout its shelf life.
How is Nagilma administered?+
Nagilma is taken orally, usually with a meal to reduce gastrointestinal discomfort. The tablets should be swallowed whole with a full glass of water and not crushed or chewed, unless otherwise directed by a healthcare professional.
What are the most serious risks associated with Nagilma?+
The most serious adverse events include lactic acidosis, which is rare but potentially fatal, especially in patients with severe renal impairment, and severe hypoglycemia when combined with insulin or sulfonylureas. Prompt medical attention is required if symptoms of either condition appear.
Who should not use Nagilma?+
Nagilma is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin, linagliptin, or any excipients, and in individuals with a history of lactic acidosis. It should also be avoided in patients with acute or chronic metabolic acidosis.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Metformin Hydrochloride, Linagliptin
Route
Oral Use
Manufacturer
Innovis Pharma
Origin
EU

Related products

Autnami

Autnami

Metformin Hydrochloride, Linagliptin

Sandoz D.O.O.
EU
Autnami

Autnami

Metformin Hydrochloride, Linagliptin

Sandoz Pharmaceuticals D.D.
EU
Autnami

Autnami

Metformin Hydrochloride, Linagliptin

Sandoz Pharmaceuticals D.D.
EU
Autnami

Autnami

Metformin Hydrochloride, Linagliptin

Sandoz Pharmaceuticals D.D.
EU